IN2012DN01234A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01234A IN2012DN01234A IN1234DEN2012A IN2012DN01234A IN 2012DN01234 A IN2012DN01234 A IN 2012DN01234A IN 1234DEN2012 A IN1234DEN2012 A IN 1234DEN2012A IN 2012DN01234 A IN2012DN01234 A IN 2012DN01234A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- well
- pharmaceutically acceptable
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09171700 | 2009-09-29 | ||
| PCT/EP2010/064217 WO2011039130A1 (en) | 2009-09-29 | 2010-09-27 | New benzimidazole derivatives and their use as fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01234A true IN2012DN01234A (enrdf_load_stackoverflow) | 2015-05-15 |
Family
ID=43033176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1234DEN2012 IN2012DN01234A (enrdf_load_stackoverflow) | 2009-09-29 | 2010-09-27 |
Country Status (12)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3043865B1 (en) | 2013-09-11 | 2020-11-04 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
| CN108072684B (zh) * | 2016-11-11 | 2020-06-16 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
| WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
| CN110944635A (zh) | 2017-03-30 | 2020-03-31 | 国家医疗保健研究所 | 用于减少附加体病毒的持久性和表达的方法和药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| AU2007263807B2 (en) | 2006-06-29 | 2011-06-02 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same |
| DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
| AU2008291148B2 (en) * | 2007-08-27 | 2011-03-17 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives used as FXR agonists |
| ES2403592T3 (es) * | 2007-11-15 | 2013-05-20 | F. Hoffmann-La Roche Ag | Nuevos derivados de bencimidazol y su empleo como agonsitas del FXR |
| JP5530445B2 (ja) * | 2008-09-11 | 2014-06-25 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ベンゾイミダゾール誘導体 |
| WO2010043513A1 (en) * | 2008-10-15 | 2010-04-22 | F. Hoffmann-La Roche Ag | New benzimidazole derivatives |
-
2010
- 2010-09-20 US US12/885,588 patent/US8309581B2/en not_active Expired - Fee Related
- 2010-09-27 JP JP2012531341A patent/JP5503007B2/ja not_active Expired - Fee Related
- 2010-09-27 BR BR112012006986A patent/BR112012006986A2/pt not_active Application Discontinuation
- 2010-09-27 EP EP10757215A patent/EP2483247A1/en not_active Withdrawn
- 2010-09-27 KR KR1020127010681A patent/KR101477872B1/ko not_active Expired - Fee Related
- 2010-09-27 CN CN201080043283.8A patent/CN102574812B/zh not_active Expired - Fee Related
- 2010-09-27 IN IN1234DEN2012 patent/IN2012DN01234A/en unknown
- 2010-09-27 WO PCT/EP2010/064217 patent/WO2011039130A1/en active Application Filing
- 2010-09-27 MX MX2012002479A patent/MX2012002479A/es active IP Right Grant
- 2010-09-27 CA CA2772815A patent/CA2772815A1/en not_active Abandoned
- 2010-09-27 AU AU2010303146A patent/AU2010303146A1/en not_active Abandoned
-
2012
- 2012-02-09 IL IL218037A patent/IL218037A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5503007B2 (ja) | 2014-05-28 |
| EP2483247A1 (en) | 2012-08-08 |
| IL218037A0 (en) | 2012-04-30 |
| CA2772815A1 (en) | 2011-04-07 |
| US8309581B2 (en) | 2012-11-13 |
| CN102574812A (zh) | 2012-07-11 |
| BR112012006986A2 (pt) | 2016-04-12 |
| AU2010303146A1 (en) | 2012-04-19 |
| CN102574812B (zh) | 2016-03-30 |
| KR101477872B1 (ko) | 2014-12-30 |
| HK1171746A1 (zh) | 2013-04-05 |
| KR20120063536A (ko) | 2012-06-15 |
| WO2011039130A1 (en) | 2011-04-07 |
| US20110077273A1 (en) | 2011-03-31 |
| MX2012002479A (es) | 2012-03-26 |
| JP2013505977A (ja) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03337A (enrdf_load_stackoverflow) | ||
| MX2010005824A (es) | Derivados de aminotiazol. | |
| MY138941A (en) | Aryl-pyridine derivatives | |
| MX2011012017A (es) | Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). | |
| TW200738241A (en) | Pyridazine derivatives | |
| UA102310C2 (ru) | Гетероциклические сульфонамиды, их применение и фармацевтические композиции | |
| GEP20125487B (en) | Organic compounds and their use | |
| IN2012DN01232A (enrdf_load_stackoverflow) | ||
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| MX2009004441A (es) | Derivados de indazol utiles como inhibidores de las isoformas de higado. | |
| TW200626558A (en) | Indazolone derivatives | |
| MX2009010218A (es) | Derivados de aza-piridopirimidinona. | |
| TW200740764A (en) | Pyrazolone derivatives | |
| PH12013500942A1 (en) | Triazolopyridine compounds | |
| TW200833324A (en) | Sulfonamide derivatives | |
| MX2012007536A (es) | Derivados de heteroarilo que contienen nitrogeno. | |
| IN2012DN00765A (enrdf_load_stackoverflow) | ||
| MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
| MX2010005714A (es) | Compuestos de piridina. | |
| MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
| MX2010001742A (es) | Nuevos derivados de piperazina-amida. | |
| PH12014501540A1 (en) | 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives | |
| GEP201606545B (en) | 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections | |
| MY183039A (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
| MX2011008360A (es) | Derivados de piridazinona sustituida con heteroarilo. |